JP2009514962A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009514962A5 JP2009514962A5 JP2008540115A JP2008540115A JP2009514962A5 JP 2009514962 A5 JP2009514962 A5 JP 2009514962A5 JP 2008540115 A JP2008540115 A JP 2008540115A JP 2008540115 A JP2008540115 A JP 2008540115A JP 2009514962 A5 JP2009514962 A5 JP 2009514962A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- compound
- independently
- aliphatic
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 73
- 125000001072 heteroaryl group Chemical group 0.000 claims 35
- 125000001931 aliphatic group Chemical group 0.000 claims 34
- 125000002723 alicyclic group Chemical group 0.000 claims 32
- 125000005843 halogen group Chemical group 0.000 claims 22
- 125000003107 substituted aryl group Chemical group 0.000 claims 20
- 229910052739 hydrogen Inorganic materials 0.000 claims 17
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 14
- 239000000203 mixture Substances 0.000 claims 14
- 125000004076 pyridyl group Chemical group 0.000 claims 14
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 150000007824 aliphatic compounds Chemical class 0.000 claims 12
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 12
- 229910052799 carbon Inorganic materials 0.000 claims 11
- 239000001257 hydrogen Substances 0.000 claims 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims 10
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 10
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 claims 8
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 claims 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000003118 aryl group Chemical group 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 6
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 6
- 150000001721 carbon Chemical group 0.000 claims 5
- 230000000694 effects Effects 0.000 claims 5
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- 229910052760 oxygen Inorganic materials 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims 4
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 3
- 239000012472 biological sample Substances 0.000 claims 3
- 125000004432 carbon atom Chemical group C* 0.000 claims 3
- 201000010064 diabetes insipidus Diseases 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- -1 R substituted E Chemical group 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 125000003342 alkenyl group Chemical group 0.000 claims 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 229910052717 sulfur Chemical group 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 102100034452 Alternative prion protein Human genes 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 102100032187 Androgen receptor Human genes 0.000 claims 1
- 206010003694 Atrophy Diseases 0.000 claims 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 claims 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 claims 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims 1
- 206010013883 Dwarfism Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000017701 Endocrine disease Diseases 0.000 claims 1
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 206010019860 Hereditary angioedema Diseases 0.000 claims 1
- 208000033981 Hereditary haemochromatosis Diseases 0.000 claims 1
- 101000775732 Homo sapiens Androgen receptor Proteins 0.000 claims 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 claims 1
- 206010020850 Hyperthyroidism Diseases 0.000 claims 1
- 208000000038 Hypoparathyroidism Diseases 0.000 claims 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 1
- 208000008955 Mucolipidoses Diseases 0.000 claims 1
- 206010072928 Mucolipidosis type II Diseases 0.000 claims 1
- 208000002678 Mucopolysaccharidoses Diseases 0.000 claims 1
- 102100026784 Myelin proteolipid protein Human genes 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 201000005118 Nephrogenic diabetes insipidus Diseases 0.000 claims 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000017493 Pelizaeus-Merzbacher disease Diseases 0.000 claims 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims 1
- 108091000054 Prion Proteins 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 201000005660 Protein C Deficiency Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000009415 Spinocerebellar Ataxias Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 208000022292 Tay-Sachs disease Diseases 0.000 claims 1
- 208000010641 Tooth disease Diseases 0.000 claims 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 claims 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 229940088710 antibiotic agent Drugs 0.000 claims 1
- 229960005475 antiinfective agent Drugs 0.000 claims 1
- 239000004599 antimicrobial Substances 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 210000003591 cerebellar nuclei Anatomy 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000392 cycloalkenyl group Chemical group 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003172 expectorant agent Substances 0.000 claims 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 claims 1
- 230000002068 genetic effect Effects 0.000 claims 1
- 208000013746 hereditary thrombophilia due to congenital protein C deficiency Diseases 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000012623 in vivo measurement Methods 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 208000020460 mucolipidosis II alpha/beta Diseases 0.000 claims 1
- 229940066491 mucolytics Drugs 0.000 claims 1
- 206010028093 mucopolysaccharidosis Diseases 0.000 claims 1
- 208000000638 myeloperoxidase deficiency Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 210000005036 nerve Anatomy 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 235000015097 nutrients Nutrition 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 125000004193 piperazinyl group Chemical group 0.000 claims 1
- 125000003386 piperidinyl group Chemical group 0.000 claims 1
- 108010040003 polyglutamine Proteins 0.000 claims 1
- 229920000155 polyglutamine Polymers 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 230000020978 protein processing Effects 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 201000003624 spinocerebellar ataxia type 1 Diseases 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 239000011593 sulfur Chemical group 0.000 claims 1
- 0 CC(*)(*)C(N(*)c1ncccc1)=O Chemical compound CC(*)(*)C(N(*)c1ncccc1)=O 0.000 description 19
- RLLDERLNXMQJRP-UHFFFAOYSA-N CC(C)c(cc1)cc(N=C)c1OC Chemical compound CC(C)c(cc1)cc(N=C)c1OC RLLDERLNXMQJRP-UHFFFAOYSA-N 0.000 description 1
- QHTKTNLJVDSPEP-UHFFFAOYSA-N CCc1ccc(CN(C)C)cc1 Chemical compound CCc1ccc(CN(C)C)cc1 QHTKTNLJVDSPEP-UHFFFAOYSA-N 0.000 description 1
- UDCVULAOQKRAGA-UHFFFAOYSA-N CN(CCO)S(c(cc1)ccc1N=C)(=O)=O Chemical compound CN(CCO)S(c(cc1)ccc1N=C)(=O)=O UDCVULAOQKRAGA-UHFFFAOYSA-N 0.000 description 1
- OVVNNFPNBWAEHO-UHFFFAOYSA-N COc(cc1)ccc1N=C Chemical compound COc(cc1)ccc1N=C OVVNNFPNBWAEHO-UHFFFAOYSA-N 0.000 description 1
- XQVCBOLNTSUFGD-UHFFFAOYSA-N COc(ccc(N)c1)c1Cl Chemical compound COc(ccc(N)c1)c1Cl XQVCBOLNTSUFGD-UHFFFAOYSA-N 0.000 description 1
- WCYZALIKRBYPOM-UHFFFAOYSA-N COc1cccc(OC)c1I Chemical compound COc1cccc(OC)c1I WCYZALIKRBYPOM-UHFFFAOYSA-N 0.000 description 1
- ZYUHQKSYYJRYEB-UHFFFAOYSA-N CS(CCc(cc1)ccc1I)(=O)=O Chemical compound CS(CCc(cc1)ccc1I)(=O)=O ZYUHQKSYYJRYEB-UHFFFAOYSA-N 0.000 description 1
- WXWCDTXEKCVRRO-UHFFFAOYSA-N Cc(cc1)cc(N)c1OC Chemical compound Cc(cc1)cc(N)c1OC WXWCDTXEKCVRRO-UHFFFAOYSA-N 0.000 description 1
- IGWGXOHABPCPHZ-UHFFFAOYSA-N Cc(cc1)ccc1S(N1CCCCC1)(=O)=O Chemical compound Cc(cc1)ccc1S(N1CCCCC1)(=O)=O IGWGXOHABPCPHZ-UHFFFAOYSA-N 0.000 description 1
- KEWLILUTGFEINV-UHFFFAOYSA-N Cc1ccc(CNC(CF)=O)cc1 Chemical compound Cc1ccc(CNC(CF)=O)cc1 KEWLILUTGFEINV-UHFFFAOYSA-N 0.000 description 1
- WBYVNDUCUMNZPM-UHFFFAOYSA-N Fc(cc1)cc(I)c1F Chemical compound Fc(cc1)cc(I)c1F WBYVNDUCUMNZPM-UHFFFAOYSA-N 0.000 description 1
- BSLVNOLUEJOXMR-UHFFFAOYSA-N Ic(cc1)cc2c1OCC2 Chemical compound Ic(cc1)cc2c1OCC2 BSLVNOLUEJOXMR-UHFFFAOYSA-N 0.000 description 1
- RIXNIROIHWVYKM-UHFFFAOYSA-N Ic1c[o]cc1 Chemical compound Ic1c[o]cc1 RIXNIROIHWVYKM-UHFFFAOYSA-N 0.000 description 1
- INJLXYOVHBVVAZ-UHFFFAOYSA-N N#Cc1ccc(C2NC2)cc1 Chemical compound N#Cc1ccc(C2NC2)cc1 INJLXYOVHBVVAZ-UHFFFAOYSA-N 0.000 description 1
- KVAUXJXBBGYOBW-UHFFFAOYSA-N Nc(cc1)ccc1S(N(CC1)CC1O)(=O)=O Chemical compound Nc(cc1)ccc1S(N(CC1)CC1O)(=O)=O KVAUXJXBBGYOBW-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US73450605P | 2005-11-08 | 2005-11-08 | |
| US60/734,506 | 2005-11-08 | ||
| US75408605P | 2005-12-27 | 2005-12-27 | |
| US60/754,086 | 2005-12-27 | ||
| US80245806P | 2006-05-22 | 2006-05-22 | |
| US60/802,458 | 2006-05-22 | ||
| PCT/US2006/043289 WO2007056341A1 (en) | 2005-11-08 | 2006-11-08 | Heterocyclic modulators of atp-binding cassette transporters |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012193199A Division JP5666525B2 (ja) | 2005-11-08 | 2012-09-03 | Ａｔｐ結合カセット輸送体モジュレータ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2009514962A JP2009514962A (ja) | 2009-04-09 |
| JP2009514962A5 true JP2009514962A5 (enExample) | 2010-12-02 |
| JP5317184B2 JP5317184B2 (ja) | 2013-10-16 |
Family
ID=37766297
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008540115A Active JP5317184B2 (ja) | 2005-11-08 | 2006-11-08 | Ａｔｐ結合カセット輸送体モジュレータ |
| JP2012193199A Active JP5666525B2 (ja) | 2005-11-08 | 2012-09-03 | Ａｔｐ結合カセット輸送体モジュレータ |
| JP2014091543A Active JP5941095B2 (ja) | 2005-11-08 | 2014-04-25 | Ａｔｐ結合カセット輸送体モジュレータ |
| JP2015094156A Pending JP2015134835A (ja) | 2005-11-08 | 2015-05-01 | Ａｔｐ結合カセット輸送体モジュレータ |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012193199A Active JP5666525B2 (ja) | 2005-11-08 | 2012-09-03 | Ａｔｐ結合カセット輸送体モジュレータ |
| JP2014091543A Active JP5941095B2 (ja) | 2005-11-08 | 2014-04-25 | Ａｔｐ結合カセット輸送体モジュレータ |
| JP2015094156A Pending JP2015134835A (ja) | 2005-11-08 | 2015-05-01 | Ａｔｐ結合カセット輸送体モジュレータ |
Country Status (23)
| Country | Link |
|---|---|
| US (18) | US7741321B2 (enExample) |
| EP (6) | EP2395002B1 (enExample) |
| JP (4) | JP5317184B2 (enExample) |
| KR (6) | KR101331768B1 (enExample) |
| CN (2) | CN101356170B (enExample) |
| AU (1) | AU2006311650B2 (enExample) |
| CA (1) | CA2627358C (enExample) |
| CY (3) | CY1115750T1 (enExample) |
| DK (4) | DK2404919T3 (enExample) |
| ES (5) | ES2778846T3 (enExample) |
| HU (2) | HUE032640T2 (enExample) |
| IL (2) | IL191141A (enExample) |
| LT (2) | LT2774925T (enExample) |
| LU (1) | LU93073I2 (enExample) |
| NL (1) | NL300812I2 (enExample) |
| NO (1) | NO20082674L (enExample) |
| NZ (1) | NZ567892A (enExample) |
| PL (4) | PL2404919T3 (enExample) |
| PT (4) | PT2395002E (enExample) |
| RU (3) | RU2463303C3 (enExample) |
| SI (4) | SI2395002T1 (enExample) |
| WO (1) | WO2007056341A1 (enExample) |
| ZA (1) | ZA200803887B (enExample) |
Families Citing this family (178)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1898221A (zh) | 2003-09-06 | 2007-01-17 | 沃泰克斯药物股份有限公司 | Atp－结合弹夹转运蛋白的调控剂 |
| US7407976B2 (en) * | 2003-11-14 | 2008-08-05 | Vertex Pharmaceuticals Incorporated | Thiazoles and oxazoles useful as modulators of ATP-Binding Cassette transporters |
| FR2864083B1 (fr) * | 2003-12-18 | 2007-04-13 | Galderma Res & Dev | Nouveaux derives d'acides phenyl-boroniques et leurs procedes de preparation. |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| WO2005075435A1 (en) * | 2004-01-30 | 2005-08-18 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| HUE032540T2 (en) | 2004-06-24 | 2017-09-28 | Vertex Pharma | Modulators of ATP-binding cassette transporters |
| CN101163478B (zh) | 2005-01-25 | 2013-11-27 | 幸讬制药公司 | 用于炎症及免疫相关用途之化合物 |
| ATE512145T1 (de) | 2005-08-11 | 2011-06-15 | Vertex Pharma | Modulatoren des cystic fibrosis transmembrane conductance regulators |
| EP2395002B1 (en) | 2005-11-08 | 2014-06-18 | Vertex Pharmaceuticals Inc. | Pharmaceutical composition containing a heterocyclic modulator of atp-binding cassette transporters. |
| US20120232059A1 (en) * | 2005-11-08 | 2012-09-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette Transporters |
| CN101395147B (zh) * | 2005-12-28 | 2013-05-29 | 弗特克斯药品有限公司 | 作为atp-结合盒转运蛋白调节剂用于治疗囊性纤维化的1-(苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(苯基)环丙烷-甲酰胺衍生物及相关化合物 |
| US7671221B2 (en) * | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| CA2635581C (en) | 2005-12-28 | 2017-02-28 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| PT2674428T (pt) | 2006-04-07 | 2016-07-14 | Vertex Pharma | Modeladores de transportadores de cassetes de ligação de atp |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| USRE50453E1 (en) | 2006-04-07 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| US10022352B2 (en) | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| CA2684105C (en) | 2007-05-03 | 2011-09-06 | Pfizer Limited | Pyridine derivatives |
| NZ581259A (en) * | 2007-05-09 | 2012-07-27 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| AU2013231028B2 (en) * | 2007-05-09 | 2016-05-26 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| EP2158183A2 (en) * | 2007-05-25 | 2010-03-03 | Vertex Pharmaceuticals Incorporated | Ion channel modulators and methods of use |
| HUE028426T2 (en) | 2007-08-24 | 2016-12-28 | Vertex Pharma | Isothiazolopyridinones for (inter alia) treating cystic fibrosis |
| ES2556080T3 (es) * | 2007-11-16 | 2016-01-12 | Vertex Pharmaceuticals Incorporated | Moduladores de isoquinolina de transportadores de casete de unión a ATP |
| AU2013231151B2 (en) * | 2007-11-16 | 2015-06-25 | Vertex Pharmaceuticals Incorporated | Isoquinoline modulators of ATP-Binding Cassette transporters |
| CA2722582A1 (en) * | 2007-11-21 | 2009-05-28 | Decode Genetics Ehf. | Biaryl pde4 inhibitors for treating inflammation |
| UA102534C2 (xx) | 2007-12-07 | 2013-07-25 | Вертекс Фармасьютикалз Инкорпорейтед | ТВЕРДА ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДІОКСОЛ-5-ІЛ)-ЦИКЛОПРОПАНКАРБОКСАМІДО)-3-МЕТИЛПІРИДИН-2-ІЛ)БЕНЗОЙНОЇ КИСЛОТИ (ВАРІАНТИ)$ТВЕРДАЯ ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДИОКСОЛ-5-ИЛ)-ЦИКЛОПРОПАНКАРБОКСАМИДО)-3-МЕТИЛПИРИДИН-2-ИЛ)БЕНЗОЙНОЙ КИСЛОТЫ (ВАРИАНТЫ) |
| US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| LT2639223T (lt) * | 2007-12-07 | 2017-06-26 | Vertex Pharmaceuticals Incorporated | Cikloalkilkarboksiamido-piridino benzenkarboksirūgščių gamybos būdas |
| AU2016200431B2 (en) * | 2007-12-07 | 2017-08-24 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| UA95199C2 (en) * | 2007-12-07 | 2011-07-11 | Вертекс Фармасьютикалз Инкорпорейтед | Aqueous formulation of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| AU2013205160B2 (en) * | 2007-12-07 | 2016-05-19 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| AU2013231109B2 (en) * | 2007-12-07 | 2015-10-29 | Vertex Pharmaceuticals Incorporated | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| AU2016204422B2 (en) * | 2007-12-07 | 2017-11-16 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| AU2015228930B2 (en) * | 2008-02-28 | 2017-02-23 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as CFTR modulators |
| NZ602030A (en) * | 2008-02-28 | 2014-02-28 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
| AU2013205162B2 (en) * | 2008-02-28 | 2015-07-09 | Vertex Pharmaceuticals Incorporated | Heteroaryl derivatives as CFTR modulators |
| AU2013270464B2 (en) * | 2008-03-31 | 2016-05-26 | Vertex Pharmaceuticals Incorporated | Pyridyl derivatives as CFTR modulators |
| NZ616097A (en) * | 2008-03-31 | 2015-04-24 | Vertex Pharma | Pyridyl derivatives as cftr modulators |
| ES2963910T3 (es) | 2008-06-26 | 2024-04-03 | Zevra Denmark As | Uso de Hsp70 como regulador de la actividad enzimática |
| US20110230428A1 (en) * | 2008-07-22 | 2011-09-22 | John Wityak | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| US8853424B2 (en) | 2008-08-11 | 2014-10-07 | Japan Science And Technology Agency | Protein cross-linking inhibitor |
| US20100256184A1 (en) * | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| US12458635B2 (en) | 2008-08-13 | 2025-11-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| GB0817207D0 (en) | 2008-09-19 | 2008-10-29 | Pimco 2664 Ltd | therapeutic apsac compounds and their use |
| MX2011003249A (es) * | 2008-09-29 | 2011-05-19 | Vertex Pharma | Unidades de dosificacion del acido 3-(6-(1-(2,2-difluorobenzo[d][1 ,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoi co. |
| AR074060A1 (es) | 2008-10-23 | 2010-12-22 | Vertex Pharma | Moduladores del regulador de conductancia transmembrana de la fibrosis quistica |
| WO2010068863A2 (en) | 2008-12-12 | 2010-06-17 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
| EP2821400B1 (en) | 2009-03-20 | 2017-09-27 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| EP2490687A1 (en) | 2009-10-22 | 2012-08-29 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
| US20130004477A1 (en) * | 2009-10-26 | 2013-01-03 | Zhe Lu | Methods for Treating Inflammation and Oxidative Stress Related Diseases |
| BR112012015916A2 (pt) * | 2009-12-31 | 2017-04-25 | Novartis Ag | derivados de pirazina e seu uso no tratamento de distúrbios neurológicos |
| US8247436B2 (en) | 2010-03-19 | 2012-08-21 | Novartis Ag | Pyridine and pyrazine derivative for the treatment of CF |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| CN102917692A (zh) | 2010-04-07 | 2013-02-06 | 弗特克斯药品有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的药物组合物和其给药方法 |
| NZ602795A (en) * | 2010-04-07 | 2015-01-30 | Vertex Pharma | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| NZ603042A (en) * | 2010-04-22 | 2015-02-27 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
| CA2797118C (en) | 2010-04-22 | 2021-03-30 | Vertex Pharmaceuticals Incorporated | Process of producing cycloalkylcarboxamido-indole compounds |
| NZ603044A (en) | 2010-04-22 | 2015-08-28 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
| EP2560650A1 (en) | 2010-04-22 | 2013-02-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| EP2560488B1 (en) | 2010-04-23 | 2015-10-28 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| PT2563776T (pt) | 2010-04-27 | 2016-09-19 | Calcimedica Inc | Compostos que modulam o cálcio intracelular |
| US10703722B2 (en) | 2010-04-27 | 2020-07-07 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| CA2797533A1 (en) | 2010-04-27 | 2011-11-10 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
| US8334292B1 (en) | 2010-06-14 | 2012-12-18 | Cystic Fibrosis Foundation Therapeutics, Inc. | Pyrimidine compounds and methods of making and using same |
| US9079891B2 (en) | 2010-08-27 | 2015-07-14 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| PT2646044T (pt) | 2010-11-30 | 2019-11-12 | Orphazyme As | Métodos para aumentar a atividade intracelular de hsp70 |
| CN102133402B (zh) * | 2011-03-24 | 2013-06-12 | 首都医科大学附属北京同仁医院 | 囊性纤维化跨膜转导调节因子抑制剂在制备治疗糖尿病药物中的应用 |
| US20120316182A1 (en) | 2011-06-10 | 2012-12-13 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| SI2750677T1 (sl) | 2011-08-30 | 2017-10-30 | Chdi Foundation, Inc. | Inhibitorji kinurenin-3-monooksigenaze, farmacevtski sestavki in postopki njihove uporabe |
| WO2013033068A1 (en) | 2011-08-30 | 2013-03-07 | Stephen Martin Courtney | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| US9856240B2 (en) | 2011-10-19 | 2018-01-02 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| AU2012335714B2 (en) | 2011-11-08 | 2017-04-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| TWI640519B (zh) * | 2011-11-29 | 2018-11-11 | 泰緯生命科技股份有限公司 | Ｈｅｃ１活性調控因子及其調節方法 |
| US20130186801A1 (en) | 2012-01-25 | 2013-07-25 | Vertex Pharmaceuticals Incorporated | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| RU2692779C2 (ru) | 2012-02-27 | 2019-06-27 | Вертекс Фармасьютикалз Инкорпорейтед | Фармацевтическая композиция и ее введения |
| US8674108B2 (en) | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
| IN2015DN01061A (enExample) | 2012-08-17 | 2015-06-26 | Bayer Cropscience Ag | |
| PL2914248T5 (pl) | 2012-11-02 | 2024-01-15 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób w których pośredniczy CFTR |
| ITMI20122065A1 (it) | 2012-12-03 | 2014-06-04 | Univ Padova | Uso dei correttori del cftr nel trattamento delle patologie del muscolo striato |
| US20140371238A1 (en) * | 2013-03-13 | 2014-12-18 | Flatley Discovery Lab | Compounds and methods for the treatment of cystic fibrosis |
| WO2014141064A1 (en) | 2013-03-13 | 2014-09-18 | Novartis Ag | Notch2 binding molecules for treating respiratory diseases |
| WO2014160440A1 (en) | 2013-03-13 | 2014-10-02 | Flatley Discovery Lab | Pyridazinone compounds and methods for the treatment of cystic fibrosis |
| WO2014186704A2 (en) * | 2013-05-17 | 2014-11-20 | N30 Pharmaceuticals, Inc. | Novel compounds for the treatment of cystic fibrosis |
| GB201311361D0 (en) | 2013-06-26 | 2013-08-14 | Pimco 2664 Ltd | Compounds and their therapeutic use |
| BR112016010403A2 (pt) | 2013-11-12 | 2017-08-08 | Vertex Pharma | Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por cftr |
| CN103664796A (zh) * | 2013-12-06 | 2014-03-26 | 辽宁师范大学 | 5-[2-(5-羧基-嘧啶基)]-1,3-苯二羧酸的合成方法 |
| WO2015143376A1 (en) * | 2014-03-21 | 2015-09-24 | Nivalis Therapeutics, Inc. | Novel compounds for the treatment of cystic fibrosis |
| CA2944140C (en) | 2014-04-15 | 2022-10-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
| EP2932966A1 (en) | 2014-04-16 | 2015-10-21 | Novartis AG | Gamma secretase inhibitors for treating respiratory diseases |
| US10258621B2 (en) | 2014-07-17 | 2019-04-16 | Chdi Foundation, Inc. | Methods and compositions for treating HIV-related disorders |
| GB201415381D0 (en) | 2014-08-29 | 2014-10-15 | Algipharma As | Inhalable powder formulations of alginate oligomers |
| HUE054957T2 (hu) | 2014-09-15 | 2021-10-28 | Orphazyme As | Arimoklomol készítése |
| AU2015328174B2 (en) | 2014-10-06 | 2020-05-21 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| RU2749213C2 (ru) | 2014-10-07 | 2021-06-07 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе |
| WO2016058544A1 (en) * | 2014-10-16 | 2016-04-21 | Syros Pharmaceuticals, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| HRP20201666T1 (hr) | 2014-10-31 | 2020-12-25 | AbbVie Overseas S.à r.l. | Supstituirani kromani i postupak njihove upotrebe |
| US10302602B2 (en) | 2014-11-18 | 2019-05-28 | Vertex Pharmaceuticals Incorporated | Process of conducting high throughput testing high performance liquid chromatography |
| CN107108508B (zh) | 2014-12-17 | 2020-09-01 | 皮姆科2664有限公司 | N-(4-羟基-4-甲基-环己基)-4-苯基-苯磺酰胺和n-(4-羟基-4-甲基-环己基)-4-(2-吡啶基)-苯磺酰胺化合物及其治疗用途 |
| CA2978007A1 (en) | 2015-02-27 | 2016-09-01 | Calcimedica, Inc. | Pancreatitis treatment |
| GB201504878D0 (en) | 2015-03-23 | 2015-05-06 | Algipharma As | Use of alginate oligomers and CFTR modulators in the treatment of conditions associated with CFTR dysfuntion |
| FR3035105A1 (fr) * | 2015-04-16 | 2016-10-21 | Metabrain Res | Derives utiles dans le traitement de l'atrophie musculaire |
| RS62639B1 (sr) | 2015-07-06 | 2021-12-31 | Alkermes Inc | Hetero-halo inhibitori histonskih deacetilaza |
| US10421756B2 (en) | 2015-07-06 | 2019-09-24 | Rodin Therapeutics, Inc. | Heterobicyclic N-aminophenyl-amides as inhibitors of histone deacetylase |
| DK3331525T3 (da) | 2015-08-07 | 2020-12-14 | Calcimedica Inc | Anvendelse af CRAC-kanal-inhibitorer til behandling af slagtilfælde og traumatisk hjerneskade |
| CN106432209A (zh) * | 2015-08-11 | 2017-02-22 | 苏州晶云药物科技有限公司 | Lumacaftor的新晶型及其制备方法 |
| US10479782B2 (en) * | 2015-09-29 | 2019-11-19 | Mylan Laboratories Limited | Forms of lumacaftor and processes for the preparation thereof |
| GB201517639D0 (en) | 2015-10-06 | 2015-11-18 | Algipharma As | Use of alginate oligomers to treat or prevent microbial overgrowth in the intestinal tract |
| US10065963B2 (en) | 2015-11-06 | 2018-09-04 | Incyte Corporation | Heterocyclic compounds as PI3K-γ inhibitors |
| WO2017118915A1 (en) * | 2016-01-04 | 2017-07-13 | Dr. Reddy's Laboratories Limited | Amorphous and crystalline solid forms of lumacaftor or its complex and preparative processes thereof |
| ES2995198T3 (en) | 2016-01-05 | 2025-02-07 | Incyte Corp | Pyridine compounds as pi3k-gamma inhibitors |
| CN107033120B (zh) * | 2016-02-03 | 2020-03-17 | 苏州旺山旺水生物医药有限公司 | 2-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)乙氰的制备方法 |
| WO2017137900A1 (en) | 2016-02-10 | 2017-08-17 | Lupin Limited | Amorphous lumacaftor and its solid dispersion |
| MX377024B (es) * | 2016-02-15 | 2025-03-07 | Taisho Pharmaceutical Co Ltd | Compuesto de piridina sustituida con azol |
| WO2017175161A1 (en) * | 2016-04-07 | 2017-10-12 | Dr. Reddy’S Laboratories Limited | Solid forms of lumacaftor, its salts and processes thereof |
| US10898476B2 (en) | 2016-04-13 | 2021-01-26 | Orphazyme A/S | Heat shock proteins and cholesterol homeostasis |
| KR101683011B1 (ko) | 2016-04-20 | 2016-12-07 | 에스텍전자 주식회사 | 플렉시블 필름히터를 적용한 온수모듈장치 및 이를 구비하는 온수매트 |
| US10383865B2 (en) | 2016-04-25 | 2019-08-20 | Druggability Technologies Ip Holdco Limited | Pharmaceutical combination composition comprising complex formulations of Ivacaftor and Lumacaftor and their salts and derivatives, process for their preparation thereof and pharmaceutical compositions containing them |
| US10206915B2 (en) | 2016-04-25 | 2019-02-19 | Druggability Technologies Ip Holdco Limited | Complexes of Ivacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| HUP1600271A2 (hu) | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Ivacaftor és Lumacaftor sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyszerészetileg elfogadható készítményei |
| HUP1600269A2 (hu) | 2016-04-25 | 2017-10-30 | Druggability Tech Ip Holdco Ltd | Lumacaftornak, sóinak és származékainak komplexei, eljárás azok elõállítására és azok gyógyászati készítményei |
| US10376501B2 (en) | 2016-04-25 | 2019-08-13 | Druggability Technologies Ip Holdco Limited | Complexes of lumacaftor and its salts and derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| RU2021117465A (ru) | 2016-04-29 | 2021-07-22 | Орфазим А/С | Аримокломол для лечения ассоциированных с глюкоцереброзидазой нарушений |
| AR108875A1 (es) | 2016-06-24 | 2018-10-03 | Incyte Corp | COMPUESTOS HETEROCÍCLICOS COMO INHIBIDORES DE PI3K-g |
| JOP20190125B1 (ar) * | 2016-12-09 | 2022-03-14 | Vertex Pharma | مُعدِّل لمنظم موصلية التليف الكيسي عبر الغشاء، وتركيبات صيدلانية، وطرق للعلاج، وعملية لتصنيع المُعدِّل |
| EP3565814B1 (en) | 2017-01-09 | 2024-07-10 | Laurus Labs Limited | Process and crystalline forms of lumacaftor |
| MD3570834T2 (ro) | 2017-01-11 | 2022-04-30 | Alkermes Inc | Inhibitori biciclici ai histon deacetilazei |
| CN108658851B (zh) * | 2017-03-27 | 2023-06-06 | 山东特珐曼药业有限公司 | 2-氯-3-甲基-6-酰基氨基吡啶及其制备方法和用途 |
| AU2018304168B2 (en) | 2017-07-17 | 2023-05-04 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| JP7152471B2 (ja) | 2017-08-07 | 2022-10-12 | ロダン・セラピューティクス，インコーポレーテッド | ヒストン脱アセチル化酵素の二環阻害剤 |
| WO2019070962A1 (en) | 2017-10-04 | 2019-04-11 | Ohio State Innovation Foundation | BICYCLIC PEPTIDE INHIBITORS |
| CA3020592A1 (en) | 2017-10-17 | 2019-04-17 | Apotex Inc. | Novel crystalline form of lumacaftor |
| CA3085006A1 (en) | 2017-12-08 | 2019-06-13 | Vertex Pharmaceuticals Incorporated | Processes for making modulators of cystic fibrosis transmembrane conductance regulator |
| WO2019136314A1 (en) | 2018-01-05 | 2019-07-11 | The Curators Of The University Of Missouri | Compounds and methods for treatment of cystic fibrosis |
| US11793884B2 (en) | 2018-01-29 | 2023-10-24 | Ohio State Innovation Foundation | Cyclic peptidyl inhibitors of CAL-PDZ binding domain |
| CN110950807B (zh) * | 2018-09-26 | 2023-03-03 | 中国科学院上海药物研究所 | 联芳基类化合物、其制备方法、药物组合物及其应用 |
| WO2020214921A1 (en) | 2019-04-17 | 2020-10-22 | Vertex Pharmaceuticals Incorporated | Solid forms of modulators of cftr |
| EP4003978B1 (en) | 2019-07-22 | 2024-05-01 | Boehringer Ingelheim International GmbH | N-methyl, n-(6-(methoxy)pyridazin-3-yl) amine derivatives as autotaxin (atx) modulators for the treatment of inflammatory airway or fibrotic diseases |
| US11465982B2 (en) * | 2019-07-22 | 2022-10-11 | Boehringer Ingelheim International Gmbh | Pyridazines |
| KR20220064366A (ko) | 2019-08-14 | 2022-05-18 | 버텍스 파마슈티칼스 인코포레이티드 | Cftr 조절제의 결정질 형태 |
| TWI867024B (zh) | 2019-08-14 | 2024-12-21 | 美商維泰克斯製藥公司 | 囊腫纖維化跨膜傳導調節蛋白之調節劑 |
| AU2020328568A1 (en) | 2019-08-14 | 2022-03-03 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230058312A1 (en) * | 2019-11-25 | 2023-02-23 | Gain Therapeutics Sa | Aryl and heteroaryl compounds, and therapeutic uses thereof in conditions associated with the alteration of the activity of galactocerebrosidase |
| TW202136238A (zh) * | 2020-01-06 | 2021-10-01 | 大陸商廣東東陽光藥業有限公司 | RORγt抑制劑及其製備方法和用途 |
| CR20230120A (es) | 2020-08-07 | 2023-09-01 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| EP3970718A1 (en) | 2020-09-18 | 2022-03-23 | Charité - Universitätsmedizin Berlin | New medical use of cystic fibrosis transmembrane conductance regulator (cftr) modulators |
| US20230416275A1 (en) | 2020-10-07 | 2023-12-28 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2022076618A1 (en) | 2020-10-07 | 2022-04-14 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230382924A1 (en) | 2020-10-07 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230374038A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US20230373939A1 (en) | 2020-10-07 | 2023-11-23 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225748A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225750A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| MX2023004072A (es) | 2020-10-07 | 2023-07-05 | Vertex Pharma | Moduladores del regulador de la conductancia transmembrana de la fibrosis quistica. |
| IL301756A (en) | 2020-10-07 | 2023-05-01 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP4225764A1 (en) | 2020-10-07 | 2023-08-16 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| US12324802B2 (en) | 2020-11-18 | 2025-06-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| IL303026A (en) | 2020-11-19 | 2023-07-01 | Zevra Denmark As | Processes for preparing arimoclomol citrate and intermediates thereof |
| EP4472983A1 (en) | 2022-02-03 | 2024-12-11 | Vertex Pharmaceuticals Incorporated | Methods of preparing and crystalline forms of (6a,12a)-17-amino-12-methyl-6,15-bis(trifluoromethyl)-13,19-dioxa-3,4,18-triazatricyclo[ 12.3.1.12,5]nonadeca-1(18),2,4,14,16-pentaen-6-ol |
| EP4472635A1 (en) | 2022-02-03 | 2024-12-11 | Vertex Pharmaceuticals Incorporated | Methods of treatment for cystic fibrosis |
| CN118974059A (zh) | 2022-02-08 | 2024-11-15 | 弗特克斯药品有限公司 | 囊性纤维化跨膜传导调控因子的调节剂 |
| WO2023196429A1 (en) | 2022-04-06 | 2023-10-12 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| CN119947720A (zh) | 2022-05-16 | 2025-05-06 | 弗特克斯药品有限公司 | 治疗囊性纤维化的方法 |
| CN119731183A (zh) | 2022-05-16 | 2025-03-28 | 弗特克斯药品有限公司 | 大环化合物作为cftr调节剂的固体形式和其制备 |
| JP2025530377A (ja) | 2022-09-15 | 2025-09-11 | イドルシア・ファーマシューティカルズ・リミテッド | 大環状ｃｆｔｒ調節剤とｃｆｔｒコレクター及び／又はｃｆｔｒポテンシエーターとの合剤 |
| JP2025531206A (ja) | 2022-09-15 | 2025-09-19 | イドルシア・ファーマシューティカルズ・リミテッド | 大環状ｃｆｔｒ調節剤 |
| WO2024072793A1 (en) * | 2022-09-26 | 2024-04-04 | Rectify Pharmaceuticals, Inc. | Pyridine carboxamide compounds and their use in treating medical conditions |
| WO2024072794A1 (en) * | 2022-09-26 | 2024-04-04 | Rectify Pharmaceuticals, Inc. | Pyridine carboxamide compounds and their use in treating medical conditions |
| WO2025076235A1 (en) | 2023-10-04 | 2025-04-10 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| WO2025123039A1 (en) * | 2023-12-08 | 2025-06-12 | Shaman Pharma, LLC | Method for Production of Spiro-Oxindole and Indoxyl Derivatives of Mitragynine |
| US20250228835A1 (en) * | 2024-01-12 | 2025-07-17 | Rectify Pharmaceuticals, Inc. | Pyridinyloxypyridines and related compounds and their use in treating medical conditions |
| WO2025186214A1 (en) | 2024-03-05 | 2025-09-12 | Idorsia Pharmaceuticals Ltd | Macrocyclic cftr modulators |
Family Cites Families (260)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3758475A (en) | 1971-07-20 | 1973-09-11 | Sandoz Ag | Pyrido(2,3-d)pyrimidin 2 ones |
| IT1226048B (it) * | 1981-12-14 | 1990-12-10 | Medea Res Srl | Composti ad attivita'antiinfiammatoria, processo per la loro preparazione e composizioni farmaceutiche relative |
| EP0081756B1 (en) | 1981-12-14 | 1985-05-15 | MEDEA RESEARCH S.r.l. | New compounds with antiinflammatory and antitussive activity, process for their preparation and relative pharmaceutical compositions |
| US4501729A (en) | 1982-12-13 | 1985-02-26 | Research Corporation | Aerosolized amiloride treatment of retained pulmonary secretions |
| EP0278374A3 (de) | 1987-02-06 | 1989-03-01 | Pharmatest Apparatebau Gmbh | Vorrichtung zur Bestimmung der Wirkstoff-Freigabe von pharmazeutischen Produkten |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US5981714A (en) | 1990-03-05 | 1999-11-09 | Genzyme Corporation | Antibodies specific for cystic fibrosis transmembrane conductance regulator and uses therefor |
| JP3167762B2 (ja) | 1990-11-27 | 2001-05-21 | 武田薬品工業株式会社 | ピリドピリダジン誘導体およびその用途 |
| US5612360A (en) | 1992-06-03 | 1997-03-18 | Eli Lilly And Company | Angiotensin II antagonists |
| CA2107196A1 (en) | 1992-09-29 | 1994-03-30 | Mitsubishi Chemical Corporation | Carboxamide derivatives |
| US6060024A (en) | 1993-07-14 | 2000-05-09 | Zymark Corporation | Automatic dissolution testing system |
| US5886026A (en) | 1993-07-19 | 1999-03-23 | Angiotech Pharmaceuticals Inc. | Anti-angiogenic compositions and methods of use |
| GB9317764D0 (en) | 1993-08-26 | 1993-10-13 | Pfizer Ltd | Therapeutic compound |
| EP0724570B1 (en) | 1993-10-21 | 1999-03-03 | G.D. Searle & Co. | Amidino derivatives useful as nitric oxide synthase inhibitors |
| DE4405712A1 (de) | 1994-02-23 | 1995-08-24 | Basf Ag | Substituierte Naphthyridine und deren Verwendung |
| IL113313A (en) | 1994-04-11 | 1999-09-22 | Sankyo Co | Heterocyclic compounds and pharmaceutical compositions containing the same |
| DE69513846T2 (de) | 1994-09-27 | 2000-07-06 | Janssen Pharmaceutica N.V., Beerse | N-substituierte piperidinyl bicyclische benzoatderivate |
| DK0788600T3 (da) | 1994-10-28 | 2002-08-05 | Sophion Bioscience As | Patch-clamp-apparat og -teknik med høj gennemgang og lave fluidvolumenkrav |
| US5656256A (en) | 1994-12-14 | 1997-08-12 | The University Of North Carolina At Chapel Hill | Methods of treating lung disease by an aerosol containing benzamil or phenamil |
| US5510379A (en) | 1994-12-19 | 1996-04-23 | Warner-Lambert Company | Sulfonate ACAT inhibitors |
| US5585115A (en) | 1995-01-09 | 1996-12-17 | Edward H. Mendell Co., Inc. | Pharmaceutical excipient having improved compressability |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| JP2000507955A (ja) | 1996-04-03 | 2000-06-27 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質転移酵素の阻害剤 |
| CA2268051A1 (en) | 1996-08-23 | 1998-02-26 | Alanex Corporation | Neuropeptide-y ligands |
| AU6013998A (en) | 1996-12-30 | 1998-07-31 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| CO4920215A1 (es) | 1997-02-14 | 2000-05-29 | Novartis Ag | Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones |
| US5948814A (en) | 1997-02-20 | 1999-09-07 | The Curators Of The University Of Missouri | Genistein for the treatment of cystic fibrosis |
| WO1998047868A1 (en) | 1997-04-18 | 1998-10-29 | Smithkline Beecham Plc | Heterocycle-containing urea derivatives as 5ht1a, 5ht1b and 5ht1d receptor antagonists |
| NZ503712A (en) | 1997-10-02 | 2003-07-25 | Sankyo Co | Amidopropionic acid derivatives |
| DK1054996T3 (da) | 1998-02-17 | 2004-05-24 | Searle & Co | Fremgangsmåde til den enzymatiske adskillelse af lactamer |
| JP2002517483A (ja) | 1998-06-08 | 2002-06-18 | シェーリング コーポレイション | 神経ペプチドｙ５レセプターアンタゴニスト |
| US6426331B1 (en) | 1998-07-08 | 2002-07-30 | Tularik Inc. | Inhibitors of STAT function |
| AUPP609198A0 (en) | 1998-09-22 | 1998-10-15 | Curtin University Of Technology | Use of non-peptidyl compounds for the treatment of insulin related ailments |
| US6444686B1 (en) | 1998-12-18 | 2002-09-03 | Brsitol-Myers Squibb Pharma Company | N-ureidoalkyl-piperidines as modulators of chemokine receptor activity |
| BR0008489A (pt) | 1999-02-24 | 2002-02-05 | Hoffmann La Roche | Derivados de fenil- e piridinila |
| RU2236402C2 (ru) | 1999-02-24 | 2004-09-20 | Ф.Хоффманн-Ля Рош Аг | Производные 3-фенилпиридина и фармацевтическая композиция на их основе |
| DK1035115T3 (da) | 1999-02-24 | 2005-01-24 | Hoffmann La Roche | 4-phenylpyridinderivater og anvendelse deraf som NK-1-receptorantagonister |
| US7407978B2 (en) * | 1999-04-06 | 2008-08-05 | Theracos, Inc. | Heterocyclic analogs of diphenylethylene compounds |
| UA71971C2 (en) | 1999-06-04 | 2005-01-17 | Agoron Pharmaceuticals Inc | Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases |
| JP2003502408A (ja) | 1999-06-18 | 2003-01-21 | バイエル アクチェンゲゼルシャフト | フェノキシフルオロピリミジン類 |
| UA74539C2 (en) | 1999-12-08 | 2006-01-16 | Pharmacia Corp | Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants) |
| AU2010601A (en) | 1999-12-16 | 2001-07-03 | Novartis Ag | Organic compounds |
| AU2930501A (en) | 2000-01-07 | 2001-07-24 | Transform Pharmaceuticals, Inc. | High-throughput formation, identification, and analysis of diverse solid-forms |
| EP1253923A1 (en) | 2000-01-28 | 2002-11-06 | Biogen, Inc. | Pharmaceutical compositions containing anti-beta 1 integrin compounds and uses |
| WO2001056989A2 (en) | 2000-02-01 | 2001-08-09 | Cor Therapeutics, Inc. | Inhibitors of factor xa |
| US20010047100A1 (en) | 2000-04-26 | 2001-11-29 | Kjaersgaard Hans Joergen | Chiral imidazoyl intermediates for the synthesis of 2-(4-imidazoyl)-cyclopropyl derivatives |
| AU2000249828A1 (en) | 2000-05-03 | 2001-11-12 | Taisho Pharmaceutical Co. Ltd. | Stat4 and stat6 binding dipeptide derivatives |
| US6499984B1 (en) | 2000-05-22 | 2002-12-31 | Warner-Lambert Company | Continuous production of pharmaceutical granulation |
| US6509333B2 (en) | 2000-06-01 | 2003-01-21 | Bristol-Myers Squibb Pharma Company | Lactams substituted by cyclic succinates as inhibitors of Aβ protein production |
| TWI259180B (en) | 2000-08-08 | 2006-08-01 | Hoffmann La Roche | 4-Phenyl-pyridine derivatives |
| ATE346064T1 (de) | 2000-09-15 | 2006-12-15 | Vertex Pharma | Pyrazolverbindungen als protein-kinasehemmer |
| JP4272338B2 (ja) | 2000-09-22 | 2009-06-03 | バイエル アクチェンゲゼルシャフト | ピリジン誘導体 |
| US20020115619A1 (en) | 2000-10-04 | 2002-08-22 | Rubenstein Ronald C. | Compositions and methods for treatment of cystic fibrosis |
| GB2367816A (en) | 2000-10-09 | 2002-04-17 | Bayer Ag | Urea- and thiourea-containing derivatives of beta-amino acids |
| AU2002212282A1 (en) | 2000-10-20 | 2002-05-06 | Merck Patent G.M.B.H | Chiral binaphthol derivatives |
| US6884782B2 (en) | 2000-11-08 | 2005-04-26 | Amgen Inc. | STAT modulators |
| ES2354249T3 (es) | 2000-12-01 | 2011-03-11 | Eisai Inc. | Derivados de azafenantridona y su uso como inhibidores de parp. |
| GB0102687D0 (en) | 2001-02-02 | 2001-03-21 | Pharmacia & Upjohn Spa | Oxazolyl-pyrazole derivatives active as kinase inhibitors,process for their preparation and pharmaceutical compositions comprising them |
| US6531597B2 (en) | 2001-02-13 | 2003-03-11 | Hoffmann-La Roche Inc. | Process for preparation of 2-phenyl acetic acid derivatives |
| US6962674B2 (en) | 2001-02-28 | 2005-11-08 | Varian, Inc. | Dissolution test apparatus |
| CA2442654A1 (en) | 2001-04-10 | 2002-10-10 | Transtech Pharma, Inc. | Probes, systems, and methods for drug discovery |
| BR0209151A (pt) | 2001-04-23 | 2004-07-13 | Hoffmann La Roche | Uso de antagonistas de receptor nk-1 contra hiperplasia prostática benigna |
| EP1392302A1 (en) | 2001-05-22 | 2004-03-03 | Neurogen Corporation | 5-substituted-2-arylpyridines as crf1 modulators |
| US20030083345A1 (en) | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
| US6627646B2 (en) | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| AU2002322585A1 (en) | 2001-07-20 | 2003-03-03 | Adipogenix, Inc. | Fat accumulation-modulating compounds |
| WO2003007945A1 (en) | 2001-07-20 | 2003-01-30 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| WO2003022852A2 (en) | 2001-09-11 | 2003-03-20 | Smithkline Beecham Corporation | Furo-and thienopyrimidine derivatives as angiogenesis inhibitors |
| PA8557501A1 (es) | 2001-11-12 | 2003-06-30 | Pfizer Prod Inc | Benzamida, heteroarilamida y amidas inversas |
| JP2003155285A (ja) | 2001-11-19 | 2003-05-27 | Toray Ind Inc | 環状含窒素誘導体 |
| JP2003221386A (ja) | 2001-11-26 | 2003-08-05 | Takeda Chem Ind Ltd | 二環性誘導体、その製造法およびその用途 |
| US20030171411A1 (en) | 2001-12-21 | 2003-09-11 | Kodra Janos Tibor | Amide derivatives as therapeutic agents |
| TW200307539A (en) | 2002-02-01 | 2003-12-16 | Bristol Myers Squibb Co | Cycloalkyl inhibitors of potassium channel function |
| TW200304820A (en) | 2002-03-25 | 2003-10-16 | Avanir Pharmaceuticals | Use of benzimidazole analogs in the treatment of cell proliferation |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| FR2840807B1 (fr) | 2002-06-12 | 2005-03-11 | Composition cosmetique de soin et/ou de maquillage, structuree par des polymeres silicones et des organogelateurs, sous forme rigide | |
| CN1703395A (zh) | 2002-08-09 | 2005-11-30 | 特兰斯泰克制药公司 | 芳基和杂芳基化合物以及调节凝血的方法 |
| GB0221443D0 (en) | 2002-09-16 | 2002-10-23 | Glaxo Group Ltd | Pyridine derivates |
| JP2006505571A (ja) | 2002-10-15 | 2006-02-16 | リゲル ファーマシューテイカルズ、インコーポレイテッド | 置換されたインドール及びｈｃｖ阻害剤としてのその使用 |
| WO2004041163A2 (en) | 2002-10-30 | 2004-05-21 | Merck & Co., Inc. | Piperidinyl cyclopentyl aryl benzylamide modulators of chemokine receptor activity |
| AU2003287449A1 (en) | 2002-10-31 | 2004-05-25 | Nanostream, Inc. | Parallel detection chromatography systems |
| WO2004047974A1 (en) | 2002-11-26 | 2004-06-10 | Universiteit Gent | Process and apparatus for continuous wet granulation of power material |
| BR0317183A (pt) | 2002-12-12 | 2005-11-01 | Pharmacia Corp | Método de usar compostos de aminocianopiridina como inibidores de proteìna quinase-2 ativada por proteìna quinase ativada por mitógeno |
| WO2004063179A1 (en) | 2003-01-06 | 2004-07-29 | Eli Lilly And Company | Substituted arylcyclopropylacetamides as glucokinase activators |
| KR20050101200A (ko) | 2003-02-10 | 2005-10-20 | 버텍스 파마슈티칼스 인코포레이티드 | Ｎ-아릴 카밤산 에스테르를 할로-헤테로아릴과반응시킴으로써 ｎ-헤테로아릴-ｎ-아릴-아민을 제조하는방법 및 유사 방법 |
| US7223788B2 (en) | 2003-02-14 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments |
| EP1601657A1 (en) * | 2003-03-12 | 2005-12-07 | Vertex Pharmaceuticals Incorporated | Pyrazole modulators of atp-binding cassette transporters |
| JP2006525329A (ja) | 2003-04-30 | 2006-11-09 | ジ インスチチュート フォー ファーマシューティカル ディスカバリー、エルエルシー | 置換カルボン酸類 |
| ATE440825T1 (de) * | 2003-06-06 | 2009-09-15 | Vertex Pharma | Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern |
| GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| AU2004253541B2 (en) * | 2003-06-27 | 2010-10-28 | Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Amphiphilic pyridinium compounds, method of making and use thereof |
| JP2005053902A (ja) | 2003-07-18 | 2005-03-03 | Nippon Nohyaku Co Ltd | フェニルピリジン類、その中間体及びこれを有効成分とする除草剤 |
| AU2004270713A1 (en) | 2003-09-05 | 2005-03-17 | Aventis Pharmaceuticals Inc. | Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands |
| CN1898221A (zh) | 2003-09-06 | 2007-01-17 | 沃泰克斯药物股份有限公司 | Atp－结合弹夹转运蛋白的调控剂 |
| KR100528925B1 (ko) * | 2003-09-09 | 2005-11-15 | 삼성에스디아이 주식회사 | 방열시트 및 이를 구비한 플라즈마 디스플레이 장치 |
| US7534894B2 (en) | 2003-09-25 | 2009-05-19 | Wyeth | Biphenyloxy-acids |
| US20050070718A1 (en) | 2003-09-30 | 2005-03-31 | Abbott Gmbh & Co. Kg | Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them |
| CA2540978A1 (en) * | 2003-10-08 | 2005-04-21 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups |
| US20070078120A1 (en) | 2003-10-21 | 2007-04-05 | Hitoshi Ban | Novel piperidine derivative |
| FR2861304B1 (fr) | 2003-10-23 | 2008-07-18 | Univ Grenoble 1 | Modulateurs des canaux cftr |
| GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
| US7407976B2 (en) * | 2003-11-14 | 2008-08-05 | Vertex Pharmaceuticals Incorporated | Thiazoles and oxazoles useful as modulators of ATP-Binding Cassette transporters |
| US20070142411A1 (en) | 2003-11-19 | 2007-06-21 | James Hagan | Use of cyclooxygenase-2 selective inhibitors for the treatment of schizophrenic disorders |
| JP3746062B2 (ja) | 2003-12-05 | 2006-02-15 | 第一製薬株式会社 | 固形製剤およびその製造方法 |
| ES2238001B1 (es) | 2004-01-21 | 2006-11-01 | Vita Cientifica, S.L. | Nuevas formas polimorficas de ondansetron, procedimientos para su preparacion, composiciones farmaceuticas que los contienen y su uso como aantiemeticos. |
| US7977322B2 (en) | 2004-08-20 | 2011-07-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| WO2005075435A1 (en) | 2004-01-30 | 2005-08-18 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| WO2005074535A2 (en) * | 2004-01-30 | 2005-08-18 | Eisai Co., Ltd. | Cholinesterase inhibitors for spinal cord disorders |
| WO2005080348A1 (ja) | 2004-02-19 | 2005-09-01 | Banyu Pharmaceutical Co., Ltd. | 新規スルホンアミド誘導体 |
| ES2241496B1 (es) | 2004-04-15 | 2006-12-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridina. |
| EP1734820A4 (en) | 2004-04-16 | 2008-01-23 | Neurogen Corp | Imidazopyrrazine, imidazopyridine, and imidazo-pyrimidine as CRF1 receptor ligands |
| EP1740575A2 (en) | 2004-04-22 | 2007-01-10 | Eli Lilly And Company | Pyrrolidine derivatives useful as bace inhibitors |
| US7585885B2 (en) | 2004-04-22 | 2009-09-08 | Eli Lilly And Company | Pyrrolidine derivatives useful as BACE inhibitors |
| AU2005249154B2 (en) | 2004-06-01 | 2011-02-10 | Luminex Molecular Diagnostics, Inc. | Method of detecting cystic fibrosis associated mutations |
| TWI547431B (zh) | 2004-06-09 | 2016-09-01 | 史密斯克萊美占公司 | 生產藥物之裝置及方法 |
| US8354427B2 (en) | 2004-06-24 | 2013-01-15 | Vertex Pharmaceutical Incorporated | Modulators of ATP-binding cassette transporters |
| US20140343098A1 (en) | 2004-06-24 | 2014-11-20 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| HUE032540T2 (en) | 2004-06-24 | 2017-09-28 | Vertex Pharma | Modulators of ATP-binding cassette transporters |
| EP1781253A1 (en) | 2004-07-01 | 2007-05-09 | Warner-Lambert Company LLC | Preparation of pharmaceutical compositions containing nanoparticles |
| AU2005269981A1 (en) | 2004-07-02 | 2006-02-09 | Bonck, John A | Tablet for pulsed delivery |
| US8188277B2 (en) | 2004-08-06 | 2012-05-29 | Otsuka Pharmaceutical Co., Ltd. | Aromatic compounds for suppressing the generation of collagen |
| CA2580838A1 (en) | 2004-09-27 | 2006-04-06 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
| WO2006040520A1 (en) | 2004-10-12 | 2006-04-20 | Astrazeneca Ab | Quinazoline derivatives |
| JP5036126B2 (ja) | 2004-10-19 | 2012-09-26 | 日医工株式会社 | エバスチン経口投与用製剤 |
| CA2587461A1 (en) | 2004-11-15 | 2006-05-18 | Pfizer Products Inc. | Azabenzoxazoles for the treatment of cns disorders |
| AU2005315591B2 (en) | 2004-12-15 | 2011-03-17 | Dompe' Farmaceutici S.P.A. | 2-arylpropionic acid derivatives and pharmaceutical compositions containing them |
| JP4790260B2 (ja) | 2004-12-22 | 2011-10-12 | 出光興産株式会社 | アントラセン誘導体を用いた有機エレクトロルミネッセンス素子 |
| US20080146612A1 (en) | 2005-01-27 | 2008-06-19 | Astrazeneca Ab | Novel Biaromatic Compounds, Inhibitors of the P2X7-Receptor |
| US7888374B2 (en) | 2005-01-28 | 2011-02-15 | Abbott Laboratories | Inhibitors of c-jun N-terminal kinases |
| JPWO2006082952A1 (ja) | 2005-02-01 | 2008-06-26 | 武田薬品工業株式会社 | アミド化合物 |
| EP1865949B1 (en) * | 2005-03-11 | 2012-11-14 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US7402596B2 (en) | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
| TWI377206B (en) | 2005-04-06 | 2012-11-21 | Theravance Inc | Crystalline form of a quinolinone-carboxamide compound |
| EP1710246A1 (en) | 2005-04-08 | 2006-10-11 | Schering Aktiengesellschaft | Sulfoximine-pyrimidine Macrocycles and the salts thereof, a process for making them, and their pharmaceutical use against cancer |
| JP2008536950A (ja) | 2005-04-18 | 2008-09-11 | ニューロジェン・コーポレーション | 置換ヘテロアリールのｃｂ１拮抗薬 |
| BRPI0610850A2 (pt) | 2005-04-19 | 2008-12-02 | Bayer Pharmaceuticals Corp | derivados de Ácido aril alquila, composiÇço farmacÊutica, medicamento, bem como uso dos referidos derivados |
| JP2008538561A (ja) | 2005-04-20 | 2008-10-30 | メルク エンド カムパニー インコーポレーテッド | アンジオテンシンｉｉ受容体アンタゴニスト |
| BRPI0610785A2 (pt) | 2005-04-22 | 2016-09-13 | Wyeth Corp | polimorfo cristalino, processo para preparar o mesmo, forma cristalina, composição, e, métodos para tratar uma doença, distúrbios, e uma condição |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| CA2609392A1 (en) * | 2005-05-24 | 2006-11-30 | Vertex Pharmaceuticals Incorporated | Modulators of atp-binding cassette transporters |
| BRPI0613535A2 (pt) | 2005-06-02 | 2011-01-18 | Bayer Cropscience Ag | derivados de heteroarila substituìda por fenilalquila |
| EP1919875A2 (en) | 2005-06-21 | 2008-05-14 | Astex Therapeutics Limited | Pyrazole derivatives and their use as pka and pkb modulators |
| US7316624B2 (en) * | 2005-07-29 | 2008-01-08 | Karsten Manufacturing Corporation | Golf club head for a hybrid golf club |
| ATE512145T1 (de) | 2005-08-11 | 2011-06-15 | Vertex Pharma | Modulatoren des cystic fibrosis transmembrane conductance regulators |
| ES2367844T3 (es) | 2005-08-11 | 2011-11-10 | Vertex Pharmaceuticals, Inc. | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística. |
| JO2722B1 (en) | 2005-09-09 | 2013-09-15 | سميث كلاين بيتشام كوربوريشن | New vehicles |
| CA2623237C (en) | 2005-09-23 | 2013-07-09 | F. Hoffmann-La Roche Ag | Novel dosage formulation |
| AU2006302371A1 (en) * | 2005-10-06 | 2007-04-19 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding cassette transporters |
| DK1940821T3 (da) | 2005-10-19 | 2013-06-10 | Gruenenthal Gmbh | Nye vanilloid-receptorligander og deres anvendelse til fremstilling af lægemidler. |
| WO2007054480A1 (en) | 2005-11-08 | 2007-05-18 | N.V. Organon | 2-(benzimidazol-1-yl)-acetamide biaryl derivatives and their use as inhibitors of the trpv1 receptor |
| US20120232059A1 (en) | 2005-11-08 | 2012-09-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette Transporters |
| EP2395002B1 (en) * | 2005-11-08 | 2014-06-18 | Vertex Pharmaceuticals Inc. | Pharmaceutical composition containing a heterocyclic modulator of atp-binding cassette transporters. |
| ES2421450T3 (es) | 2005-12-05 | 2013-09-02 | Glaxosmithkline Llc | 2-Pirimidinil-pirazolopiridinas inhibidoras de la quinasa ErbB |
| US20090105272A1 (en) | 2005-12-24 | 2009-04-23 | Grootenhuis Peter D J | Prodrugs of modulators of ABC transporters |
| AU2006331565A1 (en) * | 2005-12-27 | 2007-07-05 | Vertex Pharmaceuticals Incorporated | Compounds useful in CFTR assays and methods therewith |
| CA2635581C (en) * | 2005-12-28 | 2017-02-28 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| US7671221B2 (en) | 2005-12-28 | 2010-03-02 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| CN101395147B (zh) | 2005-12-28 | 2013-05-29 | 弗特克斯药品有限公司 | 作为atp-结合盒转运蛋白调节剂用于治疗囊性纤维化的1-(苯并[d][1,3]间二氧杂环戊烯-5-基)-n-(苯基)环丙烷-甲酰胺衍生物及相关化合物 |
| EP1966585A2 (en) | 2005-12-30 | 2008-09-10 | Caliper Life Sciences, Inc. | Integrated dissolution processing and sample transfer system |
| US7645789B2 (en) | 2006-04-07 | 2010-01-12 | Vertex Pharmaceuticals Incorporated | Indole derivatives as CFTR modulators |
| PT2674428T (pt) | 2006-04-07 | 2016-07-14 | Vertex Pharma | Modeladores de transportadores de cassetes de ligação de atp |
| US10022352B2 (en) * | 2006-04-07 | 2018-07-17 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| CN101478964B (zh) * | 2006-05-12 | 2012-02-29 | 沃泰克斯药物股份有限公司 | N-[2,4-双(1,1-二甲基乙基)-5-羟苯基]-1,4-二氢-4-氧代喹啉-3-羧酰胺的组合物 |
| RU2009120976A (ru) | 2006-11-03 | 2010-12-10 | Вертекс Фармасьютикалз Инкорпорейтед (Us) | Производные азаиндола в качестве модуляторов cftr |
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US7754739B2 (en) | 2007-05-09 | 2010-07-13 | Vertex Pharmaceuticals Incorporated | Modulators of CFTR |
| JP5318400B2 (ja) | 2006-11-20 | 2013-10-16 | 第一三共株式会社 | レボフロキサシン含有錠剤 |
| EP2097386A2 (en) | 2006-11-27 | 2009-09-09 | Novartis AG | Substituted dihydroimidazoles and their use in the treatment of tumors |
| CN101206205B (zh) | 2006-12-22 | 2011-08-10 | 中国科学院大连化学物理研究所 | 微流量液相色谱在线大体积进样的方法和专用装置 |
| CN101209399B (zh) | 2006-12-27 | 2010-07-28 | 中国科学院沈阳应用生态研究所 | 一种往复式振荡机样品安放与固定装置 |
| CN101210906A (zh) | 2006-12-29 | 2008-07-02 | 电子科技大学 | 高通量自动化药物筛选实验检测系统 |
| US20080260820A1 (en) | 2007-04-19 | 2008-10-23 | Gilles Borrelly | Oral dosage formulations of protease-resistant polypeptides |
| NZ581324A (en) | 2007-05-02 | 2012-05-25 | Portola Pharm Inc | Combination therapy with a compound acting as a platelet adp receptor inhibitor |
| NZ581259A (en) | 2007-05-09 | 2012-07-27 | Vertex Pharma | Modulators of cystic fibrosis transmembrane conductance regulator |
| ES2548292T3 (es) * | 2007-05-25 | 2015-10-15 | Vertex Pharmaceuticals Incorporated | Moduladores del regulador de la conductancia transmembrana de la fibrosis quística |
| WO2009023509A2 (en) | 2007-08-09 | 2009-02-19 | Vertex Pharmaceuticals Incorporated | Therapeutic combinations useful in treating cftr related diseases |
| HUE028426T2 (en) | 2007-08-24 | 2016-12-28 | Vertex Pharma | Isothiazolopyridinones for (inter alia) treating cystic fibrosis |
| DE102007042754A1 (de) | 2007-09-07 | 2009-03-12 | Bayer Healthcare Ag | Substituierte 6-Phenylnikotinsäuren und ihre Verwendung |
| EP2222304A2 (en) * | 2007-09-14 | 2010-09-01 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| AU2008298545B2 (en) | 2007-09-14 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| FR2921657A1 (fr) | 2007-09-28 | 2009-04-03 | Sanofi Aventis Sa | Derives de nicotinamide, leur preparation et leur application en therapeutique |
| ES2556080T3 (es) * | 2007-11-16 | 2016-01-12 | Vertex Pharmaceuticals Incorporated | Moduladores de isoquinolina de transportadores de casete de unión a ATP |
| DE102007058718A1 (de) | 2007-12-06 | 2009-06-10 | Erweka Gmbh | Vorrichtung und Verfahren zur automatischen Freisetzung und Messung von Wirkstoffen aus einer Arzneizubereitung |
| LT2639223T (lt) * | 2007-12-07 | 2017-06-26 | Vertex Pharmaceuticals Incorporated | Cikloalkilkarboksiamido-piridino benzenkarboksirūgščių gamybos būdas |
| US20100036130A1 (en) | 2007-12-07 | 2010-02-11 | Vertex Pharmaceuticals Incorporated | Processes for producing cycloalkylcarboxamido-pyridine benzoic acids |
| UA102534C2 (xx) | 2007-12-07 | 2013-07-25 | Вертекс Фармасьютикалз Инкорпорейтед | ТВЕРДА ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДІОКСОЛ-5-ІЛ)-ЦИКЛОПРОПАНКАРБОКСАМІДО)-3-МЕТИЛПІРИДИН-2-ІЛ)БЕНЗОЙНОЇ КИСЛОТИ (ВАРІАНТИ)$ТВЕРДАЯ ФОРМА 3-(6-(1-(2,2-ДИФТОРБЕНЗО$d]$1,3]-ДИОКСОЛ-5-ИЛ)-ЦИКЛОПРОПАНКАРБОКСАМИДО)-3-МЕТИЛПИРИДИН-2-ИЛ)БЕНЗОЙНОЙ КИСЛОТЫ (ВАРИАНТЫ) |
| UA95199C2 (en) | 2007-12-07 | 2011-07-11 | Вертекс Фармасьютикалз Инкорпорейтед | Aqueous formulation of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| CN101925603B (zh) * | 2007-12-13 | 2013-12-04 | 沃泰克斯药物股份有限公司 | 囊性纤维化跨膜通道调节因子的调节剂 |
| NZ602030A (en) | 2008-02-28 | 2014-02-28 | Vertex Pharma | Heteroaryl derivatives as cftr modulators |
| EP2257356B1 (en) | 2008-02-29 | 2016-12-14 | Waters Technologies Corporation | Chromatography-based monitoring and control of multiple process streams |
| NZ616097A (en) | 2008-03-31 | 2015-04-24 | Vertex Pharma | Pyridyl derivatives as cftr modulators |
| GB0813709D0 (en) | 2008-07-26 | 2008-09-03 | Univ Dundee | Method and product |
| US20100256184A1 (en) | 2008-08-13 | 2010-10-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition and administrations thereof |
| CN102231990B (zh) | 2008-08-13 | 2013-09-25 | 沃泰克斯药物股份有限公司 | N-[2，4-双(1，1-二甲基乙基)-5-羟基苯基]-1，4-二氢-4-氧代喹啉-3-甲酰胺的药物组合物和其给药 |
| US20100074949A1 (en) | 2008-08-13 | 2010-03-25 | William Rowe | Pharmaceutical composition and administration thereof |
| MX2011003249A (es) | 2008-09-29 | 2011-05-19 | Vertex Pharma | Unidades de dosificacion del acido 3-(6-(1-(2,2-difluorobenzo[d][1 ,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoi co. |
| NZ592504A (en) * | 2008-10-23 | 2013-04-26 | Vertex Pharma | Solid forms of n-(4-(7-azabicyclo[2.2.1]heptan-7-yl)-2-(trifluoromethyl)phenyl)-4-oxo-5-(trifluoromethyl)-1,4-dihydroquinoline-3-carboxamide |
| JP5645834B2 (ja) | 2008-10-23 | 2014-12-24 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜コンダクタンス制御因子の修飾因子 |
| US20110257223A1 (en) * | 2008-10-23 | 2011-10-20 | Vertex Pharmaceuticals Incorporated | Modulators of Cystic Fibrosis Transmembrane Conductance Regulator |
| AR074060A1 (es) | 2008-10-23 | 2010-12-22 | Vertex Pharma | Moduladores del regulador de conductancia transmembrana de la fibrosis quistica |
| CA2740836C (en) | 2008-10-31 | 2017-03-21 | Biomerieux, Inc. | Methods for separation, characterization and/or identification of microorganisms using spectroscopy |
| UA104876C2 (uk) | 2008-11-06 | 2014-03-25 | Вертекс Фармасьютікалз Інкорпорейтед | Модулятори atф-зв'язувальних касетних транспортерів |
| ES2532753T3 (es) | 2008-11-06 | 2015-03-31 | Vertex Pharmaceuticals Incorporated | Moduladores de transportadores del casete de unión a ATP |
| US8367660B2 (en) * | 2008-12-30 | 2013-02-05 | Vertex Pharmaceuticals Incorporated | Modulators of cystic fibrosis transmembrane conductance regulator |
| EP2821400B1 (en) | 2009-03-20 | 2017-09-27 | Vertex Pharmaceuticals Incorporated | Process for making modulators of cystic fibrosis transmembrane conductance regulator |
| CN102361856A (zh) | 2009-03-20 | 2012-02-22 | 沃泰克斯药物股份有限公司 | 囊性纤维化跨膜传导调节因子的调节剂 |
| HRP20131155T1 (hr) | 2009-05-07 | 2014-02-28 | Gea Pharma Systems Limited | Modul za proizvodnju tableta i postupak kontinuirane proizvodnje tableta |
| KR20120083416A (ko) * | 2009-09-17 | 2012-07-25 | 버텍스 파마슈티칼스 인코포레이티드 | 아자비시클릭 화합물의 제조 방법 |
| EP2490687A1 (en) * | 2009-10-22 | 2012-08-29 | Vertex Pharmaceuticals Incorporated | Compositions for treatment of cystic fibrosis and other chronic diseases |
| US8389727B2 (en) * | 2009-10-23 | 2013-03-05 | Vertex Pharmaceuticals Incorporated | Solid forms of N-(4-(7-Azabicyclo[2.2.1]Heptan-7-yl)-2-Trifluoromethyl)Phenyl)-4-Oxo-5-(Trifluoromethyl)-1,4-Dihydroquinoline-3-Carboxamide |
| JP5789611B2 (ja) | 2009-10-23 | 2015-10-07 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | 嚢胞性線維症膜コンダクタンス制御因子のモジュレーターを調製するためのプロセス |
| EP2547658A1 (en) | 2010-03-19 | 2013-01-23 | Vertex Pharmaceuticals Incorporated | Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| RU2711481C2 (ru) * | 2010-03-25 | 2020-01-17 | Вертекс Фармасьютикалз Инкорпорейтед | ТВЕРДЫЕ ФОРМЫ (R)-1-(2, 2-ДИФТОРБЕНЗО[d][1, 3]ДИОКСОЛ-5-ИЛ)-N-(1-(2, 3-ДИГИДРОКСИПРОПИЛ)-6-ФТОР-2-(1-ГИДРОКСИ-2-МЕТИЛПРОПАН-2-ИЛ)-1H-ИНДОЛ-5-ИЛ)ЦИКЛОПРОПАНКАРБОКСАМИДА |
| US8802868B2 (en) * | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| NZ602795A (en) | 2010-04-07 | 2015-01-30 | Vertex Pharma | Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| CN102917692A (zh) | 2010-04-07 | 2013-02-06 | 弗特克斯药品有限公司 | 3-(6-(1-(2,2-二氟苯并[d][1,3]二氧杂环戊烯-5-基)环丙甲酰胺基)-3-甲基吡啶-2-基)苯甲酸的药物组合物和其给药方法 |
| NZ603044A (en) | 2010-04-22 | 2015-08-28 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
| EP2560650A1 (en) | 2010-04-22 | 2013-02-27 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| NZ603042A (en) | 2010-04-22 | 2015-02-27 | Vertex Pharma | Pharmaceutical compositions comprising cftr modulators and administrations thereof |
| CA2797118C (en) | 2010-04-22 | 2021-03-30 | Vertex Pharmaceuticals Incorporated | Process of producing cycloalkylcarboxamido-indole compounds |
| US8404849B2 (en) * | 2010-05-20 | 2013-03-26 | Vertex Pharmaceuticals | Processes for producing modulators of cystic fibrosis transmembrane conductance regulator |
| EP2575814A1 (en) | 2010-05-20 | 2013-04-10 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions and administrations thereof |
| US8563593B2 (en) | 2010-06-08 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide |
| WO2012027247A2 (en) | 2010-08-23 | 2012-03-01 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof |
| NZ607494A (en) * | 2010-08-27 | 2015-04-24 | Vertex Pharma | Pharmaceutical composition and administrations thereof |
| KR101719699B1 (ko) * | 2010-10-05 | 2017-03-27 | 삼성전자주식회사 | 메모리 모듈 및 이의 제조 방법 |
| CN102058889A (zh) | 2010-11-05 | 2011-05-18 | 王定豪 | 包含抗凝血类药物的分散片及其应用 |
| US8802700B2 (en) * | 2010-12-10 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-Binding Cassette transporters |
| CN102507770A (zh) | 2011-10-25 | 2012-06-20 | 中国检验检疫科学研究院 | 检测化妆品中六氯酚的高效液相色谱法 |
| AU2012332225A1 (en) | 2011-11-02 | 2014-05-15 | Vertex Pharmaceuticals Incorporated | Use of (N- [2, 4 -bis (1, 1 -dimethylethyl) - 5 - hydroxyphenyl] - 1, 4 - dihydro - 4 - oxoquinoline - 3 - ca rboxamide) for treating CFTR mediated diseases |
| AU2012335714B2 (en) | 2011-11-08 | 2017-04-13 | Vertex Pharmaceuticals Incorporated | Modulators of ATP-binding cassette transporters |
| US20140127901A1 (en) | 2012-11-08 | 2014-05-08 | Taiwan Semiconductor Manufacturing Company, Ltd. | Low-k damage free integration scheme for copper interconnects |
| US20130186801A1 (en) | 2012-01-25 | 2013-07-25 | Vertex Pharmaceuticals Incorporated | Formulations of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid |
| US8798308B2 (en) * | 2012-02-21 | 2014-08-05 | Bose Corporation | Convective airflow using a passive radiator |
| RU2692779C2 (ru) | 2012-02-27 | 2019-06-27 | Вертекс Фармасьютикалз Инкорпорейтед | Фармацевтическая композиция и ее введения |
| US8674108B2 (en) * | 2012-04-20 | 2014-03-18 | Vertex Pharmaceuticals Incorporated | Solid forms of N-[2,4-bis(1,1-dimethylethy)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide |
| JP2013253790A (ja) | 2012-06-05 | 2013-12-19 | Chube Univ | ニバレノールの分析法 |
| EP2858645A1 (en) | 2012-06-08 | 2015-04-15 | Vertex Pharmaceuticals Incorporated | Pharmaceuticl compositions for the treatment of cftr -mediated disorders |
| AU2013290444B2 (en) | 2012-07-16 | 2018-04-26 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions of (R)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl) cyclopropanecarboxamide and administration thereof |
| RU2666534C2 (ru) * | 2012-08-06 | 2018-09-11 | Сеномикс, Инк. | Модификатор сладкого вкуса и аромата |
| US20140092376A1 (en) | 2012-10-01 | 2014-04-03 | Momentive Performance Materials, Inc. | Container and method for in-line analysis of protein compositions |
| PL2914248T5 (pl) * | 2012-11-02 | 2024-01-15 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób w których pośredniczy CFTR |
| US9636301B2 (en) | 2012-12-04 | 2017-05-02 | Arbutus Biopharma Corporation | In vitro release assay for liposome encapsulated vincristine |
| US20140221424A1 (en) * | 2013-01-30 | 2014-08-07 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for use in the treatment of cystic fibrosis |
| CN103743826B (zh) | 2013-08-28 | 2015-12-02 | 合肥久诺医药科技有限公司 | 一种阿齐沙坦的高效液相色谱分析方法 |
| CN103822976B (zh) | 2013-10-15 | 2015-05-27 | 辽宁省食品药品检验所 | 一种测定化妆品中4-甲氧基水杨酸钾的方法 |
| BR112016010403A2 (pt) | 2013-11-12 | 2017-08-08 | Vertex Pharma | Processo de preparação de composições farmacêuticas para o tratamento de doenças mediadas por cftr |
| CA2944140C (en) | 2014-04-15 | 2022-10-04 | Vertex Pharmaceuticals Incorporated | Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases |
| CN104090038B (zh) | 2014-07-07 | 2015-09-30 | 黄宏南 | 一种直接测定冬虫夏草产品中冬虫夏草多糖肽含量的方法 |
| CN104122346B (zh) | 2014-07-31 | 2016-03-16 | 国家烟草质量监督检验中心 | 一种水基胶中尿素含量的测定方法 |
| CN104122345B (zh) | 2014-07-31 | 2015-08-12 | 国家烟草质量监督检验中心 | 烟用纸中1,1,1-三羟甲基丙烷的测定方法 |
| RU2749213C2 (ru) | 2014-10-07 | 2021-06-07 | Вертекс Фармасьютикалз Инкорпорейтед | Сокристаллы модуляторов регулятора трансмембранной проводимости при кистозном фиброзе |
| US10302602B2 (en) | 2014-11-18 | 2019-05-28 | Vertex Pharmaceuticals Incorporated | Process of conducting high throughput testing high performance liquid chromatography |
| WO2016086136A1 (en) | 2014-11-26 | 2016-06-02 | Catabasis Pharmaceuticals, Inc. | Fatty acid cysteamine conjugates of cftr modulators and their use in treating medical disorders |
| MA41031A (fr) | 2014-11-26 | 2017-10-03 | Catabasis Pharmaceuticals Inc | Conjugués cystéamine-acide gras et leur utilisation comme activateurs de l'autophagie |
| CA2969587A1 (en) | 2014-12-05 | 2016-06-09 | Centre National De La Recherche Scientifique (Cnrs) | Compounds for treating cystic fibrosis |
| JP6662885B2 (ja) | 2015-01-26 | 2020-03-11 | ライジェル ファーマシューティカルズ， インコーポレイテッド | カルボン酸生物学的等価体としてのテトラゾロン |
| UY36680A (es) | 2015-05-19 | 2016-12-30 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas como inhibidores de quinasa |
| CN105890945A (zh) | 2016-04-01 | 2016-08-24 | 中国热带农业科学院分析测试中心 | 超声离心渗液进样快速测定土壤中速效钾的方法 |
| US20180280349A1 (en) | 2017-03-28 | 2018-10-04 | Vertex Pharmaceuticals Incorporated | Methods of treating cystic fibrosis in patients with residual function mutations |
-
2006
- 2006-11-08 EP EP10192912.3A patent/EP2395002B1/en active Active
- 2006-11-08 WO PCT/US2006/043289 patent/WO2007056341A1/en not_active Ceased
- 2006-11-08 EP EP14163968.2A patent/EP2774925B1/en active Active
- 2006-11-08 ES ES16205718T patent/ES2778846T3/es active Active
- 2006-11-08 PL PL10191575T patent/PL2404919T3/pl unknown
- 2006-11-08 PT PT101929123T patent/PT2395002E/pt unknown
- 2006-11-08 CN CN2006800505211A patent/CN101356170B/zh active Active
- 2006-11-08 PT PT141639682T patent/PT2774925T/pt unknown
- 2006-11-08 KR KR1020087013765A patent/KR101331768B1/ko active Active
- 2006-11-08 DK DK10191575.9T patent/DK2404919T3/da active
- 2006-11-08 PL PL10192912T patent/PL2395002T3/pl unknown
- 2006-11-08 SI SI200631826T patent/SI2395002T1/sl unknown
- 2006-11-08 KR KR1020137007109A patent/KR20130042034A/ko not_active Ceased
- 2006-11-08 EP EP10191575.9A patent/EP2404919B1/en active Active
- 2006-11-08 ES ES10191575T patent/ES2431388T3/es active Active
- 2006-11-08 DK DK10192912.3T patent/DK2395002T3/da active
- 2006-11-08 DK DK14163968.2T patent/DK2774925T3/en active
- 2006-11-08 PT PT101915759T patent/PT2404919E/pt unknown
- 2006-11-08 LT LTEP14163968.2T patent/LT2774925T/lt unknown
- 2006-11-08 RU RU2008122929A patent/RU2463303C3/ru active Protection Beyond IP Right Term
- 2006-11-08 ES ES10192912.3T patent/ES2501594T3/es active Active
- 2006-11-08 EP EP16205718.6A patent/EP3208272B1/en active Active
- 2006-11-08 PL PL14163968T patent/PL2774925T3/pl unknown
- 2006-11-08 KR KR1020167014530A patent/KR20160067985A/ko not_active Ceased
- 2006-11-08 EP EP06837028.7A patent/EP1945632B1/en active Active
- 2006-11-08 ES ES06837028.7T patent/ES2439736T3/es active Active
- 2006-11-08 EP EP20150602.9A patent/EP3696174A1/en active Pending
- 2006-11-08 NZ NZ567892A patent/NZ567892A/en unknown
- 2006-11-08 JP JP2008540115A patent/JP5317184B2/ja active Active
- 2006-11-08 KR KR1020137032983A patent/KR101561482B1/ko active Active
- 2006-11-08 ZA ZA200803887A patent/ZA200803887B/xx unknown
- 2006-11-08 HU HUE14163968A patent/HUE032640T2/en unknown
- 2006-11-08 SI SI200632154A patent/SI2774925T1/sl unknown
- 2006-11-08 PT PT68370287T patent/PT1945632E/pt unknown
- 2006-11-08 KR KR1020137007108A patent/KR20130034062A/ko not_active Ceased
- 2006-11-08 US US11/594,431 patent/US7741321B2/en active Active
- 2006-11-08 PL PL06837028T patent/PL1945632T3/pl unknown
- 2006-11-08 DK DK06837028.7T patent/DK1945632T3/da active
- 2006-11-08 AU AU2006311650A patent/AU2006311650B2/en not_active Expired - Fee Related
- 2006-11-08 SI SI200631695T patent/SI2404919T1/sl unknown
- 2006-11-08 SI SI200631716T patent/SI1945632T1/sl unknown
- 2006-11-08 CA CA2627358A patent/CA2627358C/en active Active
- 2006-11-08 CN CN201210278199.5A patent/CN102775396B/zh active Active
- 2006-11-08 ES ES14163968.2T patent/ES2619608T3/es active Active
- 2006-11-08 KR KR1020157007929A patent/KR20150041174A/ko not_active Ceased
-
2007
- 2007-05-18 US US11/804,726 patent/US7659268B2/en active Active
-
2008
- 2008-04-29 IL IL191141A patent/IL191141A/en active IP Right Grant
- 2008-05-05 US US12/114,935 patent/US8993600B2/en active Active
- 2008-06-09 NO NO20082674A patent/NO20082674L/no not_active Application Discontinuation
-
2009
- 2009-12-04 US US12/630,874 patent/US7956052B2/en active Active
-
2010
- 2010-04-28 US US12/768,894 patent/US7973038B2/en active Active
-
2011
- 2011-03-23 US US13/069,889 patent/US8324207B2/en active Active
- 2011-05-16 US US13/108,077 patent/US8318733B2/en active Active
-
2012
- 2012-06-05 RU RU2012123372A patent/RU2608610C2/ru not_active Application Discontinuation
- 2012-08-27 US US13/595,225 patent/US8461156B2/en active Active
- 2012-09-03 JP JP2012193199A patent/JP5666525B2/ja active Active
- 2012-10-31 IL IL222784A patent/IL222784A/en active IP Right Grant
-
2013
- 2013-04-26 US US13/871,356 patent/US8741933B2/en active Active
- 2013-04-26 US US13/871,364 patent/US9216969B2/en active Active
- 2013-04-26 US US13/871,349 patent/US20130245010A1/en not_active Abandoned
- 2013-05-06 US US13/887,839 patent/US20130245011A1/en not_active Abandoned
-
2014
- 2014-04-25 JP JP2014091543A patent/JP5941095B2/ja active Active
- 2014-09-15 CY CY20141100743T patent/CY1115750T1/el unknown
-
2015
- 2015-05-01 JP JP2015094156A patent/JP2015134835A/ja active Pending
- 2015-10-28 US US14/925,804 patent/US20160143898A1/en not_active Abandoned
-
2016
- 2016-05-13 LT LTPA2016015C patent/LTC2404919I2/lt unknown
- 2016-05-17 CY CY2016012C patent/CY2016012I2/el unknown
- 2016-05-17 HU HUS1600023C patent/HUS1600023I1/hu unknown
- 2016-05-17 LU LU93073C patent/LU93073I2/fr unknown
- 2016-05-18 NL NL300812C patent/NL300812I2/nl unknown
- 2016-06-01 US US15/170,263 patent/US20180282311A9/en not_active Abandoned
- 2016-06-03 US US15/173,325 patent/US20170107206A1/en not_active Abandoned
- 2016-12-21 RU RU2016150386A patent/RU2765714C2/ru active
-
2017
- 2017-03-22 CY CY20171100364T patent/CY1118768T1/el unknown
-
2018
- 2018-11-21 US US16/197,732 patent/US10626111B2/en not_active Expired - Lifetime
-
2020
- 2020-02-13 US US16/789,945 patent/US11084804B2/en active Active
-
2021
- 2021-06-29 US US17/362,597 patent/US20220153729A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009514962A5 (enExample) | ||
| JP7196217B2 (ja) | 重水素化されたｃｆｔｒ増強剤の投与 | |
| RU2011122646A (ru) | Модуляторы переносчиков атф-связывающих кассет | |
| JP2010539185A5 (enExample) | ||
| RU2008118001A (ru) | Модуляторы атф-зависимых транспортеров | |
| RU2008122929A (ru) | Гетероциклические модуляторы транспортеров атф-связывающей кассеты | |
| JP7258924B2 (ja) | ブルトンチロシンキナーゼの阻害剤を含む剤形組成物 | |
| JP6746569B2 (ja) | 嚢胞性線維症膜貫通コンダクタンス制御因子のモジュレーターの共結晶 | |
| AU2017352206B2 (en) | Methods of treatment with deuterated CFTR potentiators | |
| RU2006120549A (ru) | Тиазолы и оксазолы, применяемые в качестве модуляторов транспортеров арт-связывающей кассеты | |
| ES2604480T3 (es) | Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il) ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas | |
| JP2009521468A5 (enExample) | ||
| JP2011516420A5 (enExample) | ||
| JP2009522277A5 (enExample) | ||
| RU2013157877A (ru) | Модуляторы атф-связывающих кассетных транспортеров | |
| JP2013508414A5 (enExample) | ||
| JP2010526831A5 (enExample) | ||
| CN1221254C (zh) | 新的作为药用配制品的血清素激动剂(5ht2)和拮抗剂(5ht6)复合剂 | |
| SK284201B6 (sk) | Kryštalická forma III hydrátu atorvastatínu, to je semivápenatej soli kyseliny [(R)-(R*,R*)-2-(4-fluórfenyl)-beta, delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4-((fenylamino)- karbonyl)-1H-pyrol-1-heptánovej, farmaceutická kompozícia obsahujúca túto kryštalickú formu a táto kryštalická forma na použitie ako liečivo | |
| JP2012514038A5 (enExample) | ||
| AU2011242457A1 (en) | Pharmaceutical compositions and administrations thereof | |
| ES2889916T3 (es) | Un procedimiento para la preparación de pirroles con actividades hipolipidémicas e hipocolesterémicas | |
| CA2634113A1 (en) | Quinolin- 4 - one derivatives as modulators of abc transporters | |
| AU2011242454A1 (en) | Pharmaceutical compositions and administrations thereof | |
| SK284202B6 (sk) | Kryštalické formy I, II a IV atorvastatínu, to je semivápenatej soli kyseliny [R-(R*,R*)]-2-(4-fluórfenyl)-beta,delta-dihydroxy- 5-(1-metyletyl)-3-fenyl-4-(fenylamino)karbonyl]-1H-pyrol-1- heptánovej, alebo jeho hydrátu, farmaceutické kompozície obsahujúce uvedené kryštalické formy a kryštalické formy na použitie ako liečivo |